EGAPP Summary

Summary of Key Changes to OMB Package

Updates to OMB package, Determining Stakeholder Awareness and the Use and Impact of Products Developed by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Model Project, have been made in order to clarify issues on data analysis and usage. We have also taken this opportunity to utilize knowledge and experience gained since the inception of the EGAPP project to update the narrative, tables, and surveys, remove any material that is no longer applicable, and reduce the overall complexity of the package. We have considered the fact that questions on oversight of genetic testing have led to high recent awareness, particularly among policy makers and consumers. Substantial changes to the package are highlighted below:

• Use of convenience or non-probability samples has been acknowledged and more appropriately described, with discussion of the potential for specific biases as appropriate.

• Estimation of the number of respondents required has been slightly revised in accordance with the use of non-probability sampling.

  • The expected burden is slightly reduced, and revisions and recalculations on burden have been done.

  • Fewer healthcare payer and policymaker respondents have been included based on experience and more recent interactions.

• The number of survey distributions has been collapsed from four to two. The original reason for the lag between the first health care provider/payer survey and the policy/consumer surveys was the lack of awareness in those audiences at that time and the perceived need to allow more time for diffusion of information. In the intervening period, policy makers and consumers have become very involved and we believe this lag time is no longer necessary.

• Survey instruments have been reviewed for redundancy and pertinence, based on lessons learned during operation of EGAPP